This newsletter presents you the following key sessions:
1. PODCAST with dr. Eggermont about pembrolizumab after complete resection of high-risk stage III
melanoma
2. Sustained clinical benefit of ramucirumab plus erlotinib over erlotinib alone in EGFR mutated, previously
untreated metastatic non-small cell lung cancer, irrespective of the mutation type
3. Nivolumab plus chemotherapy as a potential new standard first-line treatment option for patients with
advanced gastric and oesophageal cancers
4. Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence in patients with high-risk
early HR+/HER2- breast cancer
5. Lorlatinib conveys a significant clinical benefit as a first-line therapy for ALK-positive non-small cell lung
cancer patients